Abstract: A method of obtaining conjugated estrogens from pregnant mare's urine by supercritical fluid extraction and the product thus obtained is disclosed.

Abstract: In one aspect, disclosed herein is a method for determining sulfate concentration in a sample, comprising: a) providing a liquid sample comprising urea and at least one impurity; b) concentrating the liquid sample under conditions effective to reduce the liquid volume; c) forming a dilute sample solution by diluting the concentrated liquid sample of step b) in water; and d) analyzing the dilute sample solution of step c) with ion chromatography to determine if a concentration of sulfate is present in the provided liquid sample of step a); wherein the analyzing of step d) is capable of determining the presence of a sulfate concentration present in an amount less than about 1 ppm.

Abstract: A method for obtaining an extract containing the natural mixture of conjugated equine estrogens by liquid-liquid extraction of the mixture of conjugated equine estrogens, wherein the mixture obtained is depleted in non-conjugated lipophilic compounds selected from the group consisting of non-conjugated flavonoids, non-conjugated isoflavonoids, non-conjugated norisoprenoids, non-conjugated steroids, in particular androstane and pregnane steroids, and comparable non-conjugated compounds.

Abstract: The present invention is a lure optimized for a particular animal such as deer. The optimized lure is made using urine from only two animals urinating at approximately the same time. The animals can be either male or female, but preferably, females in estrus are used for optimal results. This mixture of urine is not diluted in any manner with that of additional animals or preservatives. The urine for the lure is obtained by using a single stall exclusively for only two animals for the purpose of gathering urine. This technique has been especially effective in attracting wandering bucks in rut.

Abstract: The invention relates to the field of immunology. Specifically, the invention relates to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides for an immunoregulator (IR), use of an IR in preparing a pharmaceutical composition for treating an immune-mediated disorder and a method for treating an immune-mediated disorder.

Abstract: The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein.

Abstract: The present invention relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-HIV activity. The present invention further relates to pharmaceutical compositions comprising such fractions for treating the effects of HIV infection.

Abstract: The present invention relates to peptides of one or more portions of the human chorionic gonadotropin &bgr;-chain as well as methods for treatment and prevention of diseases, including HIV infection, using human chorionic gonadotropin, employing the &bgr;-chain of human chorionic gonadotropin, peptides containing a sequence of one or more portions of the &bgr;-chain of human chorionic gonadotropin and derivatives and analogues thereof. The invention further relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-HIV activity. The present invention further relates to pharmaceutical compositions for treating and/or preventing HIV infection.

Abstract: A stabilized insect mating disruption pheromone compositions comprising an insect pheromone and 2,2′-Methylenebis(6-t-butyl-p-cresol). Methods of use and microcapsules containing these compositions are also provided.

Abstract: A method for luring animals, repelling animals and training animals and a product used therewith comprising microporous beads having animal attractant scents, animal repellant scents and animal training scents, respectively, imbibed within the beads. The beads with the animal attractant scents are configured to release the animal attractant scents in order to attract a predetermined animal. Likewise, the beads with the animal repellant scents are configured to release the animal repellant scents in order to repel a predetermined animal. Similarly, the beads with the animal training scents are placed onto a predetermined location and a predetermined animal is trained to perform a predetermined sequence using the beads.

Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided. Also provided are methods for the treatment of polycystic ovarian syndrome (PCOS) by long term administration of IGF/IGFBP-3 complex.

Abstract: The simulation of mammalian male reproductive secretions or seminal fluids by specific odoriferous chemical compounds comprised of 1-Methyl Pyrrolidine, 1-Methyl-2-Pyrrolidine Methanol, 1-Methyl-2 Pyrrolidine Ethanol, Pyrrolidine and 2-Pyrrolidone either alone or in various combinations with one another. The simulated seminal fluid's novel odor and appearance is enhanced by the incorporation of various thickeners, suspending agents, solvents, coloring agents, preservatives and surfactants.

Abstract: The present invention relates to animal scent attractants. More particularly, the present invention relates to a composition of matter for amplifying and preserving animal scents. Fox urine, coyote urine, deer urine, elk urine, moose urine, bear urine, rabbit urine, fish oils, and sheep manure are examples of substances which can be used with the present invention.

Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.

Abstract: A semi-solid deer attractant lure comprised of liquid deer urine plus a sufficient amount of flavorless gelatin to produce a semi-solid rubbery composition is disclosed. Also disclosed is a method of making and a method of using the deer attractant lure composition.

Abstract: A method for obtaining an extract from urine of pregnant mares containing a natural mixture of conjugated estrogens by solid-phase extraction of the mixture of conjugated estrogens from the urine of pregnant mares on RP silica gel.

Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carders to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.

Abstract: The subject of the present invention is a peptide structure comprising at leastthe sequence 106-116 of a .beta.-CG or a .beta.-LHa sequence of at least 5 amino acids containing at least one lysine residue.These structures may be used for the preparation of vaccines intended to control fertility.

Abstract: A two color, partially encapsulated medicament that is both tamper resistant and tamper evident comprises at least one pharmaceutically active ingredient, suitable carrier materials and excipients that are compressed into an ovoid, generally cylindrical caplet that is partially encapsulated by its insertion into the body or cap portion of a gelatin capsule.

Abstract: Disclosed here are novel compositions and methods which can be used as a blood substitute to ameliorate adverse physiological effects of blood loss. The novel compositions comprise fluids containing water, electrolytes, glycerol, and additional energy sources.